PHARMAC is pleased to announce the approval of an agreement with Apotex NZ Limited relating to the supply of diltiazem hydrochloride CD (Apo-Diltiazem CD) for the treatment of hypertension, angina, and certain heart rhythm disorders. This was the subject of a consultation letter dated 7 April 2015.

This decision results in:

• long-acting diltiazem hydrochloride (Apo-Diltiazem CD) remaining listed;
• subsidy and delisting protection for Apo-Diltiazem CD until 30 June 2018; and
• the price and subsidy of Apo-Diltiazem CD in Section B (Community) and Section H (Hospital) of the Pharmaceutical Schedule remaining the same

For more details, go to: http://www.pharmac.health.nz/news/notification-2015-05-25-approval-of-proposal-relating-to-the-listing-of-diltiazem-hydrochloride-apo-diltiazem/